Phase III
New Haven, Conn.-based BioXcel Therapeutics launched a wholly-owned subsidiary, OnkosXcel, to focus on oncology.
Pharma giant Moderna has shared data on the development of a new bivalent COVID-19 booster vaccine that performs better than its first booster that is currently on the market.
The data collected from the cut-off demonstrates that patients can maintain an average of 9.6 months without disease progression after the initial dosage of the tislelizumab-chemotherapy treatment.
In honor of World Hemophilia Day, BioSpace takes a look at some of the facts relating to the disease, and some of the highlights in recent hemophilia research and development.
TG Therapeutics voluntarily withdrew its pending BLA and supplemental NDA for its treatment dubbed U2 for adults with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
Regeneron announced that the U.S. FDA has extended its review of the BLA for monoclonal antibody REGEN-COV, which treats COVID-19.
The new facility is expected to bolster innovation across all facets of manufacturing to allow the company to fully develop and commercialize cancer treatments for patients in need.
CG Oncology presented positive interim Phase II results for its Core1 trial studying the use of CG0070 at the American Association for Cancer Research (AACR) Annual Meeting.
Bristol Myers Squibb and Nektar Therapeutics ended their global clinical program for potential bladder cancer and renal cell carcinoma treatment.
PRESS RELEASES